A Study to Evaluate Pharmacoeconomics of Antihypertensive Drugs in a Tertiary Care Teaching Hospital
Abstract
Background: Hypertension is a major public health problem associated with large health burden as well as high economic burden at individual and population levels. A prospective observational study carried out in in-patients admitted to general medicine department of tertiary care hospital to evaluate the most cost effective therapy among the monotherapy of Amlodipine and combination therapy of telmisartan + hydrochlorthiazide.
Methods: A total of 120 Hypertensive patients case records prescribed with monotherapy of Amlodipine and combination therapy of Telma H were reviewed and evaluated using descriptive statistics and ‘p’ value and assessed for their financial burden based on the cost per tablet for an year, Cost effectiveness ratio for the patients with controlled Blood Pressure by using a particular drug.
Results: Out of 120 patients females were more (59.2%) and most of them were under the age group of 41-60 years. Majority of the patients had a known history of hypertension (65%). Most of the patients were prescribed with Telma H 40/12.5mg (40%) followed with Amlong 5mg (35.8%). There was a significant positive correlation (i.e., p value= 0.05) between persistence patterns of patients with drug therapy. Probability of patients with controlled Blood Pressure taking Amlong 10 mg were 82.35% followed by patients with Amlong 5mg.
Conclusion: This study clearly showed that monotherapy of amlodipine is the most cost effective therapy than combination therapy of Telma H in order to reduce financial burden to the patient as well as to decrease the complications.
Keywords: Hypertension, Pharmacoeconomics, Cost effectiveness, Blood Pressure.
Downloads
References
2. Bhusal A, Jadhav PR, Deshmukh YA. Assessment of medication adherence among hypertensive patients: a cross-sectional study. Int J basics Clin Pharmacol, 2016; 5(4):1606-1612.
3. Bolivar JJ. Essential Hypertension an approach to its etiology and neurogenic pathophysiology. Int J Hypertens, 2013; 2013:1-11.
4. Alefan Q, Tariq AR, Ibrahim MI, Ayub A. Cost effectiveness of antihypertensive treatments in Malaysia. Malaysian J pharm sci, 2009; 7(2):137-152.
5. Ilesanmi OS, Kehinde Ige O, Adebiyi AO. The managed hypertensive: the costs of blood pressure control in Nigeria town. Pan Afr Med J. 2012; 12(96):1-9.
6. Dhivya PS, Swathy G, Siddhartha P. Pharmacoeconomics of antihypertensive drugs prescribed in a multispeciality hospital in South India. Asian j pharm, 2014; 8:178-182.
7. Esposti LD, Martino MD, Saragoni S, Sgreccia A, Capone A, Buda S, Esposti ED. Pharmacoeconomics of antihypertensive drug treatment: An analysis of how long patients remain on various antihypertensive therapies. The J Clin Hypertens, 2004; 6(2):76-83.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.